Vaccination with long NY-ESO-1 79-108 peptide and CpG-B leads to robust activation of CD4 and CD8 T cell responses in stage III/IV melanoma patients, and a new HLA-DR7 epitope

Míreanna Comhchosúla

• Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8(+) and CD4(+) T-cell responses with multiple specificities including a novel DR7-restricted epitope
  le: Baumgaertner, P., et al.
  Foilsithe: (2016)
• BTLA mediates inhibition of human tumor-specific CD8(+) T cells that can be partially reversed by vaccination
  le: Derré, Laurent, et al.
  Foilsithe: (2009)
• Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
  le: Jäger, Elke, et al.
  Foilsithe: (2000)
• Distinct sets of αβ TCRs confer similar recognition of tumor antigen NY-ESO-1(157–165) by interacting with its central Met/Trp residues
  le: Derré, Laurent, et al.
  Foilsithe: (2008)
• Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141(+) dendritic cells to activate naïve and memory NY-ESO-1-specific CD8(+) T cells
  le: Masterman, Kelly-Anne, et al.
  Foilsithe: (2020)